Rinvoq ER 15 MG tablet UU 30S
Ended Awarded Last action
- Contract number
- SPE2DR26F88ML
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $16,660
Award facts
- Contract value 100% obligated
- $16,659.78 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $16,659.78 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-unit package) on January 14, 2026, with an ultimate completion date of January 15, 2026. This competitively awarded, non-set-aside contract reflects a firm fixed-price arrangement typical of pharmaceutical supply orders under the DLA Medical Supply Chain. The work will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania.
This delivery order is issued under AmerisourceBergen Drug Corp's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.999 billion prime contract vehicle designated SPE2DX that extends through December 2026. The parent company, Cencora, Inc. (doing business as AmerisourceBergen), maintains this comprehensive global pharmaceutical support agreement to supply military healthcare programs worldwide with a wide range of pharmaceutical products, including specialty medications, brand-name and generic drugs, vaccines, and medical supplies across multiple therapeutic domains. RINVOQ (upadacitinib) is a Janus kinase inhibitor used in the treatment of inflammatory conditions, representing the type of specialized pharmaceutical product the company routinely delivers to support Defense Health Agency operations and military treatment facilities.
Quick answers
Who was awarded contract SPE2DR26F88ML?
SPE2DR26F88ML was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 14, 2026.
How much is contract SPE2DR26F88ML worth?
The government has obligated $16,660 on SPE2DR26F88ML.
Is contract SPE2DR26F88ML an order under another contract?
Yes. SPE2DR26F88ML is a delivery order under SPE2DR25D3010, an indefinite delivery contract.
Was contract SPE2DR26F88ML competed?
The extent of competition for SPE2DR26F88ML was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award